Schlösser Felix J V, Tangelder Marco J D, Verhagen Hence J M, van der Heijden Geert J M G, Muhs Bart E, van der Graaf Yolanda, Moll Frans L
Department of Vascular Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.
J Vasc Surg. 2008 Jun;47(6):1127-33. doi: 10.1016/j.jvs.2008.01.041. Epub 2008 Apr 28.
Evidence regarding the influence of cardiovascular risk factors, comorbidities, and patient characteristics on the growth of small abdominal aortic aneurysms (AAA) is limited. We assessed, in an observational cohort study, rupture rates, risks of mortality, and the effects of cardiovascular risk factors and patient demographics on growth rates of small AAAs.
Between September 1996 and January 2005, 5057 patients with manifest arterial vascular disease or cardiovascular risk factors were included in the Second Manifestation of ARTerial disease (SMART) study. Measurements of the abdominal aortic diameter were performed in all patients. All patients with an initial AAA diameter between 30 and 55 mm were selected for this study. All AAA measurements during follow-up until August 2007 were collected. Multivariate regression analysis was performed to calculate the effects of demographic patient characteristics, initial AAA diameter, and cardiovascular risk factors on AAA growth.
Included were 230 patients, with a mean age of 66 years and 90% were male. Seven AAA ruptures (six fatal) occurred in 755 patient years of follow-up (rupture rate 0.9% per patient-year). In 147 patients, AAA measurements were performed for a period of more than 6 months. The median follow-up time was 3.3 years (mean 4.0, range 0.5 to 11.1 years, standard deviation (SD) 2.5). Mean AAA diameter was 38.8 mm (SD 6.8) and mean expansion rate 2.5 mm/y. Patients using lipid-lowering drugs had a 1.2 mm/y (95% confidence interval [CI] -2.34 to -0.060 mm/y) lower AAA growth rate compared to nonusers of these drugs. Initial AAA diameter was associated with a 0.09 mm/y (95% CI 0.01 to 0.18 mm/y) higher growth rate per millimetre increase of the diameter. No other factors, including blood lipid values, were independently associated with AAA growth.
Lipid-lowering drug treatment and initial AAA diameter appear to be independently associated with lower AAA growth rates. The risk of rupture of these small abdominal aortic aneurysms was low, which pleads for watchful waiting.
关于心血管危险因素、合并症及患者特征对小腹主动脉瘤(AAA)生长影响的证据有限。在一项观察性队列研究中,我们评估了小AAA的破裂率、死亡率风险以及心血管危险因素和患者人口统计学特征对其生长率的影响。
在1996年9月至2005年1月期间,5057例患有明显动脉血管疾病或心血管危险因素的患者被纳入动脉疾病二次表现(SMART)研究。对所有患者进行腹主动脉直径测量。本研究选取所有初始AAA直径在30至55毫米之间的患者。收集随访至2007年8月期间所有AAA测量值。进行多变量回归分析以计算患者人口统计学特征、初始AAA直径和心血管危险因素对AAA生长的影响。
纳入230例患者,平均年龄66岁,90%为男性。在755患者年的随访中发生7例AAA破裂(6例致命)(破裂率为每年每患者0.9%)。147例患者进行了超过6个月的AAA测量。中位随访时间为3.3年(平均4.0年,范围0.5至11.1年,标准差(SD)2.5)。平均AAA直径为38.8毫米(SD 6.8),平均扩张率为每年2.5毫米。与未使用降脂药物的患者相比,使用降脂药物的患者AAA生长率每年低1.2毫米(95%置信区间[CI] -2.34至-0.060毫米/年)。初始AAA直径每增加1毫米,生长率每年高0.09毫米(95% CI 0.01至0.18毫米/年)。没有其他因素,包括血脂值,与AAA生长独立相关。
降脂药物治疗和初始AAA直径似乎与较低的AAA生长率独立相关。这些小腹主动脉瘤的破裂风险较低,这支持密切观察等待。